Teysuno (Tegafur/Gimeracil/Oteracil)

Teysuno is available at Insulinhub in brand and generic.

For more info on generic medicines made by Intas click here

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

European Teysuno brand is manufactured at the following 2 sites: Nordic Pharma Tolweg 15 3741 LM Baarn The Netherlands Millmount Healthcare Limited Block7, City North Business Campus, Stamullen Co. Meath, K32 YD60 Ireland

Information about Teysuno (Tegafur/Gimeracil/Oteracil)

Teysuno is a combination medication that contains three active ingredients: tegafur, gimeracil, and oteracil. This combination is used primarily in the treatment of cancer, specifically for cancers such as colorectal cancer. Teysuno works by inhibiting the growth of cancer cells, combining the effects of tegafur (a prodrug of 5-fluorouracil, an anticancer agent) with gimeracil and oteracil, which protect healthy tissues and enhance the therapeutic effect of tegafur.

Tegafur is the main chemotherapy agent, which is metabolized into the active drug 5-fluorouracil in the body.

Gimeracil prevents the breakdown of 5-fluorouracil, allowing it to stay active in the body longer.

Oteracil helps to protect normal tissues, particularly the gastrointestinal tract, from the harmful side effects of 5-fluorouracil.

Product Highlights

• Teysuno is commonly used as a first-line or adjuvant treatment for advanced or metastatic colorectal cancer.
• While primarily indicated for colorectal cancer, Teysuno may also be considered for the treatment of other solid tumors depending on clinical judgment.

Key Ingredient

• Tegafur
• Gimeracil
• Oteracil

Key Benefits

• The combination of tegafur, gimeracil, and oteracil enhances the anticancer effects of 5-fluorouracil while reducing toxicity.
• Teysuno provides a convenient oral option for cancer treatment, which can improve adherence compared to intravenous chemotherapy.
• Oteracil helps to protect the gastrointestinal tract, reducing the common side effects like diarrhea and mucositis associated with traditional chemotherapy.

Direction of Use

• The recommended dose of Teysuno is typically 75 mg/m² of tegafur (calculated based on body surface area), administered twice daily. The precise dosage and treatment schedule depend on the specific cancer type, stage, and patient condition.
• The tablets should be taken orally, typically with water, and preferably after meals. It is important to follow the prescribed schedule and not skip doses.
• If a dose is missed, take it as soon as possible, unless it is nearly time for the next dose. Do not double the dose to make up for a missed one.

Safety Concerns

• Teysuno can cause suppression of bone marrow function, leading to low blood cell counts (e.g., anemia, neutropenia, thrombocytopenia). Regular blood tests are required to monitor for these effects.
• Side effects such as nausea, vomiting, diarrhea, and mucositis can occur, although the protective action of oteracil helps mitigate some of these issues.
• Hepatic and renal function should be monitored as the drug may affect these organs, especially in patients with pre-existing conditions.
• Teysuno can be harmful to a developing fetus and should not be used during pregnancy. It may also affect fertility, so contraception is advised during treatment.

Avoid Teysuno (Tegafur/Gimeracil/Oteracil) If

• You are pregnant or planning to become pregnant, as Teysuno can cause harm to the fetus.
• You are breastfeeding, as the drug may pass into breast milk and harm the infant.
• You have severe liver or kidney impairment, as Teysuno may exacerbate these conditions.
• You have a history of hypersensitivity to any of the components of Teysuno, including tegafur, gimeracil, or oteracil.
• You have active infections or other conditions that affect the immune system, as the drug may weaken your immune response.